Janssen’s psoriasis drug shows promise for childhood diabetes Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK
AbbVie’s Skyrizi shows promise as personalised treatment for psoriasis The immunosuppressant reduced inflammation in patients with the skin condition after three days